AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 21 min read$QTTB

ORBIMED ADVISORS LLC purchased $5.0M of QTTB (indirect holdings)

ORBIMED ADVISORS LLC purchased 625,000 indirectly-held shares of Q32 Bio Inc. (QTTB) at $8.00 ($5.00M total) on 2026-05-28.

Original reporting
SEC EDGAR · ORBIMED ADVISORS LLC
Published Jun 2, 2026, 1:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$QTTB
Bullish
medium confidence
Mentioned
$QTTB
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QTTBBullishLow
01

Why it matters

The disclosed $5.0M purchase may slightly improve sentiment, but it does not introduce new clinical, regulatory, financial, or deal information.

02

Market read

Traders may treat the filing as a modest bullish read-through, but expect limited follow-through absent additional catalysts.

03

What to watch

No 10b5-1 plan is cited, but the article still lacks context on prior intent, valuation rationale, or whether other holders are buying/selling.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-01; transaction dated 2026-05-28 (post-trade disclosure).

Background

The article is an SEC Form 4 insider transaction disclosure for Q32 Bio Inc. (QTTB).

Company-level read

Ticker impact

$QTTBBullishMedium confidence
Context

ORBIMED ADVISORS LLC (10% owner/director) bought 625,000 shares of Q32 Bio Inc. in an open-market Form 4 transaction worth $5.0M.

Expected impact

Likely limited near-term impact; may modestly support sentiment rather than drive a repricing.

Evidence & confidence

The filing is a disclosed ownership increase, but no new operational/clinical/regulatory information is provided, and Form 4 timing is often non-informational (10b5-1 not used, but still not a new catalyst).

Market effects

Sector

Minimal; this is company-specific ownership activity with no stated sector-wide signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Open-market buying by a large holder can be routine portfolio rebalancing rather than a forward-looking signal, especially without accompanying news.

Key entities

  • issuer
    Q32 Bio Inc.

    Subject of the Form 4; received a $5.0M open-market purchase by ORBIMED ADVISORS LLC.

  • 10% owner/director
    ORBIMED ADVISORS LLC

    Reported indirect ownership increase via purchase of 625,000 shares at $8.00/share.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

QTTB insider trading history →

Related articles

SEP 14
$QTTBMedAI 8/10

Q32 Bio Appoints New CMO And CDO To Support Advancement Of Bempikibart

Q32 Bio Inc. (QTTB) appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. The company is advancing Bempikibart into late-stage development for alopecia areata, with a registration-directed program planned for 2027. Bempikibart showed promising results in early trials, including hair regrowth and a well-tolerated safety profile. QTTB's stock is currently trading at $11.14, up 0.39%.

rttnews.com2 min
SEP 5
$AAPLHighAI 8/10

Why Did AAPL, QTTB, CSX Stocks Surge To 52-Week Highs Today?

Apple (AAPL), Q32 Bio (QTTB), and CSX Corp. (CSX) reached 52-week highs. AAPL rose 0.6% to $323.45; Citi raised its target to $365. QTTB surged 90% after positive clinical data; Wells Fargo upgraded it to 'Overweight' with a $66 target. CSX gained 0.4% to $49.90; Raymond James lifted its target to $56. Year-to-date gains: AAPL +16%, CSX +36%, QTTB +543%.

stocktwits.com2 min
AUG 5
$QTTBMedAI 8/10

Q32 Bio Inc. (QTTB): Results of Operations and Financial Condition

Q32 Bio Inc. (QTTB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented

SEC EDGAR 8-K6 min
JUL 15
$QTTBMedAI 8/10

Why Is Q32 Bio Stock Falling Wednesday? - Q32 Bio (NASDAQ:QTTB)

Q32 Bio (NASDAQ:QTTB) fell after announcing a $200M offering. It plans to sell 6,027,399 common shares at $18.25 and pre-funded warrants for 4,931,506 shares at $18.2499, with a $0.0001 exercise price. Underwriters may buy 1,643,835 more shares. Net proceeds fund working capital and bempikibart Phase 2 alopecia areata trials. Analysts expect Aug. 5 earnings.

benzinga.com4 min
JUL 15
$QTTBMedAI 9/10

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Q32 Bio Inc. (Nasdaq: QTTB) priced an underwritten public offering of 6,027,399 shares at $18.25 each and pre-funded warrants for 4,931,506 shares at $18.2499 per warrant. Gross proceeds are expected at about $200 million, with a 30-day option for up to 1,643,835 more shares. Net proceeds will fund working capital and bempikibart (ADX-914) development. Closing is expected around July 16, 2026.

prnewswire.com2 min
JUL 14
$QTTBMedAI 8/10

Why Q32 Bio Stock Skyrocketed Today

Q32 Bio shares (QTTB) rose 90.72% after the company reported Phase 2a results for bempikibart in severe alopecia areata. The trial met its primary efficacy goal, with patients showing a 35% average reduction in scalp hair loss severity over 36 weeks, and no serious treatment-related adverse events. The stock later fell about 7% after a $200M offering; Oppenheimer raised its price target to $40.

fool.com4 min